ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Transcription profile in preoperative aromatase inhibitor response test in breast cancer patients
About authors
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
Correspondence should be addressed: Olga Vladimirovna Burmenskaya
Akademika Oparina, 4, Moscow, 117997, Russia; ur.liam@aksnemruob
About paper
Funding: the study was partially supported under the State Task "Personification of adjuvant treatment of patients with luminal HER2-negative subtypes of breast cancer enabled by a preoperative hormone sensitivity test" (state registry number in the Unified State R&D Efforts Registration System (EGISU NIOKTR): 124020600031-3).
Author contribution: VV Rodionov — study conceptualization and design; MV Rodionova, VV Kometova — material collection and processing; DYu Trofimov, OV Burmenskaya — PCR testing; OV Burmenskaya — analysis of the results, statistical processing of the data, manuscript authoring; VV Rodionov, DYu Trofimov — editing.
Compliance with ethical standards: the study was approved by the Committee on Biomedical Ethics of V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology (Minutes #03 of March 21, 2024). All patients signed an informed consent to participate in the study.
Received: 2024-11-08
Accepted: 2024-12-05
Published online: 2024-12-21
|
Today, preoperative hormone therapy is a standard procedure in the context of treatment of ESR+/HER2-negative early-stage breast cancer. Transcription profiles of genes helps make assessment of effectiveness of this therapy more accurate. This study aimed to investigate the changes in gene expression caused by the preoperative aromatase inhibitor response test in postmenopausal women with ESR+/HER2-negative breast cancer. The participants were 100 breast cancer patients treated at the Department of Breast Pathology of Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology. We did a pathomorphological study of FFPE blocks (trephine biopsied before the hormone response test was prescribed) and intraoperative samples, and immunohistochemical (Ki67, ER, PR, HER2/neu) and molecular genetic studies of 45 target genes (quantitative RT-PCR). Aromatase inhibitors in the preoperative hormone response test caused significant changes in the mRNA expression of 37 genes in breast tumors: for 35 of them (ESR1, PGR, AR, ERBB2, FGFR4, MKI67, MYBL2, CCNB1, AURKA, BIRC5, CCND1, CCNE1, CDKN2A, KIF14, PPP2R2A, PTTG1, TMEM45B, TPX2, ANLN, MMP11, CTSL2, EMSY, PAK1, BCL2, BAG1, PTEN, TYMS, EXO1, UBE2T, NAT1, SCGB2A2, GATA3, FOXA1, ZNF703, CD274/PD-L1) the level was decreased, and for 2 genes it increased (SFRP1, KRT5). The results of this study can be used in the development of a hormone sensitivity test and personification of adjuvant systemic treatment for breast cancer patients.
Keywords: ESR+/Her2-negative breast cancer, mRNA gene expression, aromatase inhibitors, letrozole, real-time reverse transcription polymerase chain reaction, RT-qPCR